Because transient elevations of serum transaminase levels have been observed during the course of succimer therapy, serum transaminases should be monitored prior to the initiation of therapy and at least weekly during therapy, particularly in patients with a history of liver disease. ❋ Unknown (2010)
Almost all the transaminases that catalyze these reactions descend from a common ancestor, illustrating once again that effective solutions to biochemical problems are retained throughout evolution (Figure 24.1). ❋ Unknown (2010)
Mild, transient elevations of serum transaminases have been observed in approximately 6-10percent of the patients (adults and children) receiving succimer therapy. ❋ Unknown (2010)
In three placebo-controlled, 12-week trials, the incidence of consecutive elevations (= 3 X ULN) in serum transaminases were 1.7 percent overall for patients treated with Vytorin and 2.6 percent for patients treated with Vytorin 10/80 mg. ❋ Unknown (2008)
In controlled long-term (48-week) extensions, which included both newly-treated and previously-treated patients, the incidence of consecutive elevations (= 3 X ULN) in serum transaminases was 1.8 percent overall and 3.6 percent for patients treated with Vytorin 10/80 mg. ❋ Unknown (2008)
These elevations in transaminases were generally asymptomatic, not associated with cholestasis and returned to baseline after discontinuation of therapy or with continued treatment. ❋ Unknown (2008)
Vytorin should not be taken by anyone with active liver disease or unexplained persistent elevations of serum transaminases. ❋ Unknown (2008)
Patient says he doesn't drink but the transaminases are off the wall and his CBC shows macrocytosis. blood test results strongly suggestive of alcoholism ❋ 1 Dinosaur (2007)
* Complete blood count, chemistry profile (including serum transaminases and lipid profile); ❋ Unknown (2001)
Complete blood count, chemistry profile (including serum transaminases and lipid profile); ❋ Unknown (2001)
One high-dose subject developed elevated levels of transaminases, an indicator of possible liver damage, and another had a slight increase in liver enzymes. ❋ Unknown (2011)
Patients with hepatitis B or C or marked elevations in transaminases are at risk of further transaminase elevations or hepatic decompensation.
Therefore if the liver continues to produce fat (from sugars, etc.) or receive deliveries of fat (e.g. released from fat stores) and is unable to burn this off in the production of energy (fat oxidation), fat stored in the liver will increase, resulting in an increase in transaminases [liver enzymes]. ❋ David Phillips (2010)
As in other mipomersen trials, elevations in liver transaminases were observed that were similar in magnitude and duration to those seen in other studies. ❋ Unknown (2010)
One patient discontinued due to elevations in liver transaminases. ❋ Editors (2010)
Consistent with previous studies evaluating mipomersen, among the most commonly observed adverse events were injection site reactions, flu-like symptoms and elevations in liver transaminases. ❋ Editors (2010)
However, isolated elevations in transaminases and bilirubin have been observed. ❋ C-F Xu (2010)
Combining all three trials, the most common side effects have been GI disturbances such as diarrhea, elevated blood pressure, transient and mild neutropenia, increased transaminases and a slight increase in infections, although not serious or opportunistic infections. ❋ Unknown (2010)
